The thesis
Momentum SMA20 Rider is a textbook trend-rider. It ranks a 24-name large-cap universe by how far each price sits above its SMA50, buys the leaders once price is confirmed above the SMA20, and rotates capital into stronger ranks when the book is full. Exits are rule-driven: it cuts a position when RSI14 pushes past 75 (overbought) or price closes back below the SMA20 (trend structure broken). It is a "let winners run, cut the rest" design, and the statistics bear that out.
What the backtest says
Over 1,233 trading days the strategy turned a start stake into $18,100.23 — an 81% total return, or about 12.89% CAGR. The headline oddity is a 37.13% win rate across 1,427 trades: most individual trades lose, yet the book compounds because the winners are allowed to run far beyond the losers. That is the signature of trend-following, not a bug.
The risk side is less flattering. The Sharpe of 0.98 is respectable but not exceptional, the max drawdown reaches 20.91%, and turnover is extreme at roughly 26,972% — the strategy churns constantly, and with a fee logged on every trade, cost drag is a structural headwind rather than a rounding error.
Does it hold up out of sample?
Validation passed the gate, and the detail is more convincing than a single number. Across four walk-forward folds, three were positive, and the most recent fold (May 2025 → Aug 2026) is the standout: +43.48% at a 2.18 Sharpe with only a 5.38% drawdown. The probabilistic Sharpe ratio of 0.986 is strong. But the honest caveat lives in the deflated Sharpe ratio of 0.583, which discounts for the 24 trials run — still positive, yet far more modest than the raw figures suggest.
The weak link is Fold 3 (Feb 2024 → May 2025): essentially flat at −0.28% with a 23% drawdown. Momentum simply did not work in that regime, and anyone deploying this should expect stretches where it bleeds sideways through chop.
Recent activity
On 2026-10-29 the strategy executed five buys — ABBV, V, CVX, XOM and WMT — a notably defensive, energy- and staples-tilted basket rather than high-beta tech. The two scheduled runs since (Oct 30 and Nov 2) executed nothing: the book is full and holding, with cash steady at $904.91 and total equity drifting around $10,000. The code reviewer approved it at risk 0.3, flagging only "minor robustness gaps around missing budget and null-momentum sentinel" — worth tracking, but not blocking.
Verdict
Momentum SMA20 Rider is a well-constructed, genuinely validated trend-follower whose edge survived out-of-sample testing. The risks are the familiar ones: punishing turnover and fees, a low hit rate that demands patience, 20%+ drawdowns, and at least one historical regime where it went nowhere. Promising, but not a strategy to size into without a tolerance for the flat stretches.